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Background: Transcriptional control of mitochondrial metabolism is essential for cellular function. A better
understanding of this process will aid the elucidation of mitochondrial disorders, in particular of the many
genetically unsolved cases of oxidative phosphorylation (OXPHOS) deficiency. Yet, to date only few studies have
investigated nuclear gene regulation in the context of OXPHOS deficiency. In this study we performed RNA
sequencing of two control and two complex I-deficient patient cell lines cultured in the presence of compounds
that perturb mitochondrial metabolism: chloramphenicol, AICAR, or resveratrol. We combined this with a
comprehensive analysis of mitochondrial and nuclear gene expression patterns, co-expression calculations and
transcription factor binding sites.
Results: Our analyses show that subsets of mitochondrial OXPHOS genes respond opposingly to chloramphenicol
and AICAR, whereas the response of nuclear OXPHOS genes is less consistent between cell lines and treatments.
Across all samples nuclear OXPHOS genes have a significantly higher co-expression with each other than with other
genes, including those encoding mitochondrial proteins. We found no evidence for complex-specific mRNA
expression regulation: subunits of different OXPHOS complexes are similarly (co-)expressed and regulated by a
common set of transcription factors. However, we did observe significant differences between the expression of
nuclear genes for OXPHOS subunits versus assembly factors, suggesting divergent transcription programs.
Furthermore, complex I co-expression calculations identified 684 genes with a likely role in OXPHOS biogenesis and
function. Analysis of evolutionarily conserved transcription factor binding sites in the promoters of these genes
revealed almost all known OXPHOS regulators (including GABP, NRF1/2, SP1, YY1, E-box factors) and a set of novel
candidates (ELK1, KLF7, SP4, EHF, ZNF143, and TEL2).
Conclusions: OXPHOS genes share an expression program distinct from other genes encoding mitochondrial
proteins, indicative of targeted nuclear regulation of a mitochondrial sub-process. Within the subset of OXPHOS
genes we established a difference in expression between mitochondrial and nuclear genes, and between nuclear
genes encoding subunits and assembly factors. Most transcription regulators of genes that co-express with complex
I are well-established factors for OXPHOS biogenesis. For the remaining six factors we here suggest for the first time
a link with transcription regulation in OXPHOS deficiency.
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Mitochondria are the primary source of cellular ATP,
which is generated via electron transfer in the oxidative
phosphorylation (OXPHOS) system using substrates
derived from oxidation of carbohydrates, fatty acids and
amino acids. The value of healthy mitochondria becomes
evident in cases of OXPHOS deficiency. These metabolic
disorders primarily affect tissues with a high ATP de-
mand such as the brain, heart, and skeletal muscle,
typically resulting in progressive energy deficiencies and
childhood death [1]. Respiratory chain disorders occur
in approximately 1:5,000–10,000 living births [2]. The
most frequently encountered one is complex I deficiency
(OMIM: 252010). No cure for OXPHOS deficiencies ex-
ists, and current interventions are either cumbersome or
only effective for specific types of the disease [3]. Fur-
thermore, 40–70 % of cases remain genetically unex-
plained [4, 5] as no mutations are found in the genes
encoding structural subunits or assembly factors, imped-
ing genetic counseling. Therefore there is a great need
for a better understanding of how the biogenesis and
activity of the OXPHOS system is controlled.
Cells can control metabolic output by regulating gene
expression. The OXPHOS system is constructed from a
combination of nuclear and mitochondrial gene prod-
ucts, e.g. seven genes of complex I are encoded by the
mitochondrial DNA and 37 by the nuclear DNA. This
bigenomic assembly implies that there are at least two
mechanisms for regulating OXPHOS gene expression:
mitochondrial and nuclear. Replication, maintenance,
and transcription of mitochondrial DNA are tightly reg-
ulated processes. Disturbances in any of these processes
have been firmly linked to combined OXPHOS deficiency
(for a recent review see [6]). In contrast, although much
has been published about the relevance of metabolic (co)-
regulators such as PGC-1α, NRF1, NRF2, YY1, and SP1
for the regulation of OXPHOS gene expression, little is
known about the possible relationship between disturbed
nuclear gene regulation and OXPHOS deficiency.
In this study, we investigate mitochondrial and nuclear
gene expression patterns in patients with complex I defi-
ciency under various conditions of perturbed mitochondrial
metabolism. Gene expression clustering, co-expression
calculations and analysis of transcription factor binding
sites provide insights into nuclear transcription regulation
of OXPHOS, suggesting regulation of the system as a whole
rather than regulation of specific complexes. Our data also
reveal that assembly factors follow an expression pattern
that is more like genes encoding other mitochondrial pro-
teins than like OXPHOS subunits. Finally, analysis of
enriched regulators of nuclear genes co-expressing with
complex I not only retrieves virtually all transcription
factors (TFs) with a well-known role in the regulation of
OXPHOS gene expression, but also identifies severalfactors not previously implicated in the regulation of
OXPHOS in general or in respiratory chain disease.
Results
Culturing, incubation and RNA sequencing of complex
I-deficient patient cells
To investigate patterns of transcription in OXPHOS
deficiency, we measured gene expression in two healthy
fibroblast cell lines and two fibroblast patient cell lines
carrying mutations in complex I genes NDUFS2 and
ND5 (Fig. 1). Cells were treated with vehicle (DMSO) and
three compounds that stimulate or inhibit mitochondrial
metabolism in order to trigger a transcriptional response
of mitochondrial genes. Chloramphenicol inhibits mito-
chondrial gene translation and OXPHOS assembly and
function [7]. Resveratrol stimulates mitochondrial growth/
metabolism via SIRT1/AMPK [8]. AICAR stimulates
mitochondrial metabolism as an AMPK agonist [9]. The
compound incubations were done in duplicate, resulting
in a total of 4 cell lines × 4 compounds × 2 replicates = 32
samples. Processing of the RNA sequencing data revealed
expression values of 13,684 nuclear DNA encoded genes
(referred to as nuclear genes) and 16 mitochondrial DNA
encoded genes (referred to as mitochondrial genes) in all
samples. We subsequently analyzed the transcriptomes
using three approaches: gene expression clustering, co-
expression calculations, and transcription factor binding
site analysis (Fig. 1).
Of our list of currently known 127 unique OXPHOS
subunits and assembly factors (Additional file 1: Table S1),
all 13 mitochondrial and 112 nuclear OXPHOS genes were
detected in the expression analysis. To investigate the
distribution of OXPHOS genes in the 13,700 expression
profiles we performed hierarchical clustering (Pearson
uncentered, average linkage). Many OXPHOS genes share
a distinct expression profile across the experiments
and are significantly enriched among a sub-cluster of
1,518 genes (48/1,518 were OXPHOS, Fisher’s exact
P < 0.05, Additional file 2: Figure S1 and Additional
file 3: Table S2). Next we analyzed mitochondrial and
nuclear OXPHOS gene expression separately.
Differences in expression of mitochondrial OXPHOS genes
between cell lines and treatments
mRNA measurements for mtDNA-encoded genes are
strongly correlated between biological replicates (R2 = 0.88,
see Methods). Total mitochondrial mRNA expression
was not significantly different between the four cell
lines (one-way ANOVA P = 0.6) indicating that differ-
ences in the genetic background of our cells do not
have a systematic influence on total mitochondrial
gene expression. mRNA expression of mitochondrial
genes in control vs. patient cells differed less than 1 %
implying that the complex I defects do not influence
Fig. 1 Overview of the approach. Two control and two complex I-deficient patient fibroblast cell lines were incubated for three days with vehicle
(DMSO) and three compounds that trigger a metabolic response and RNA was harvested in duplicate for RNA sequencing. Expression values of
individual genes across the resulting 4 × 4 × 2 = 32 samples were measured, normalized and clustered. This allowed for the analysis of expression
profiles per gene. Genes were ranked based on the similarity of their expression profile (co-expression) with the average profile for a bait set of
genes, such as the OXPHOS system or complex I. High ranking genes were analyzed for the presence of conserved transcription factor binding
sites across 29 mammals. Common, over-represented binding sites are (potential) transcriptional regulators of the system
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Figure S2A). We did, however, observe a significant
transcriptional response in cells upon perturbation of
metabolism using different compounds (4 treatments,
one-way ANOVA P = 0.0002). The total mitochondrial
mRNA expression was 15 % higher upon chloram-
phenicol treatment compared to control DMSO, and
significantly higher than any of the other treatments
(P < 0.0003 in pairwise comparison with the other
groups, two-tailed paired T-test) (Additional file 2:
Figure S3). We observed high transcript abundance
upon chloramphenicol treatments in all cell types. The
variance in chloramphenicol-induced gene expression
is very low compared to other treatments and the con-
trol condition, suggesting saturation of mitochondrial
transcript abundance (Additional file 2: Figure S3).
Total mtDNA gene expression levels in AICAR and resver-
atrol treatments are lower than control 4 % (P = 0.1) and
5 % (P = 0.001), respectively.
mRNA levels of mitochondrial OXPHOS genes change
in response to treatments (Fig. 2a). These changes in
transcript levels can be the result of a combination of
factors, such as changes in mitochondrial transcription,
in mitochondrial mRNA degradation rates, and in traf-
ficking. The direction of mRNA changes upon treat-
ments vary considerably between genes even within the
same complex. For example, the transcript level of MT-
ND2 increases by 50 % upon chloramphenicol treatment
compared to vehicle, while other subunits of complex I
(MT-ND4, MT-ND5, MT-ND6) decrease up to 30 %
(Fig. 2a and Additional file 2: Figure S4). We did not
observe correlations between changes in mitochondrial
gene expression and respiratory chain complex, position
on the mitochondrial genome or mitochondrial strand
of origin (data not shown). However, certain trends are ap-
parent and reproducible. Up-regulation of genes encodingcomplex I subunits: MT-ND4, 4L, 5 and 6 upon AICAR
treatment (~40 %) and their down regulation in chloram-
phenicol (~10 %) is significant compared to cells treated
with control DMSO (P < 0.05 or less for these genes, two-
tailed paired T-test). MT-ND2 and, to a lesser extent MT-
ND3 and MT-ATP8 show the opposite expression pattern:
they are up regulated in chloramphenicol compared to
AICAR (140–270 %, P < 0.05). Thus, mitochondrial gene
expression is similar between cell lines but different upon
treatment versus control vehicle, as subsets of mitochon-
drial OXPHOS genes respond differently to chloram-
phenicol and AICAR.
Differences in expression of nuclear OXPHOS genes
between cell lines and treatments
Examination of the expression data for nuclear genes sug-
gests differences in steady state and treatment-induced
OXPHOS mRNA levels between control and patient cell
lines, with control 2 generally showing higher nuclear
OXPHOS gene expression than the other cell lines
(Additional file 2: Figure S2B). Furthermore, the
chloramphenicol-induced accumulation of transcripts for
a subset of mitochondrial OXPHOS genes (Fig. 2a) is not
matched by nuclear OXPHOS mRNA levels (Fig. 2b). For
nuclear complex I genes, unsupervised clustering captures
similarity of transcriptional responses to AICAR and
resveratrol in closely-knit clusters (Additional file 2:
Figure S6), but these responses are not consistent for all
genes. Nevertheless, combining the gene expression pro-
files across all cell lines and treatment conditions is highly
informative, as will be illustrated in the following sections.
Clustering identifies distinct expression patterns of
OXPHOS subunits and assembly factors
Detailed analysis of the expression levels of nuclear
OXPHOS genes revealed no specific clusters for individual
Fig. 2 (See legend on next page.)
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Fig. 2 Mitochondrial OXPHOS genes respond differentially to treatments and assembly factors tend to express differently from nuclear genes
encoding OXPHOS subunits. Expression profiles of OXPHOS genes are shown in heatmap representation in 32 RNA sequencing measurements of
control and complex I-deficient patient cells. Panel a shows the mitochondrial-encoded OXPHOS genes. Panel b shows the nuclear-encoded
OXPHOS genes. At the top of the figure, controls, patients, and compound incubations are indicated across the samples, where numbers 1 and 2
refer to the cell line. On the right assembly factors and subunits per complex are labeled by color. On the left the central cluster of OXPHOS
subunit genes is indicated by a vertical bar. Genes were clustered using average linkage clustering with uncentered Pearson correlation as
distance matrix. On the bottom the horizontal bar depicts expression values. A value of 1.0 (black) denotes median log-expression of the
gene (see Methods), with green denoting higher and red denoting lower expression levels
van der Lee et al. BMC Genomics  (2015) 16:691 Page 5 of 13OXPHOS complexes, arguing against complex-specific
regulation of expression for the evaluated cell types and
conditions (Fig. 2b). However, clustering did highlight a
distinction between the expression profiles of OXPHOS
subunits and assembly factor genes: 67 of the 81
genes (83 %) in the central largest cluster are subunit
genes, while 28 of the 32 genes (82 %) in the remaining
smaller clusters are assembly genes (Fig. 2b). Thus,
although OXPHOS genes share similar expression pro-
files, subunits cluster together in a distinct group from
OXPHOS assembly genes, indicative of differential tran-
scription regulation.
Co-expression confirms absence of OXPHOS complex-
specific expression profiles and differential behavior of
assembly factors
To identify additional candidates with expression profiles
compatible with OXPHOS genes, we calculated co-
expression with complex I for all measured nuclear genes
by integrating the gene expression profiles (Fig. 1). As ex-
pected, known OXPHOS genes as a group have signifi-
cantly higher co-expression with complex I than do other
genes in the genome (Figs. 3a and b, P = 3.1 × 10−28, one-
tailed Mann–Whitney U test). However, OXPHOS genes
are also more co-expressed with complex I than other
genes encoding proteins localized to the mitochondria
[10] (P = 2.5 × 10−15). Sub-classification of OXPHOS genes
into assembly factors and the structural subunits of the
five complexes (Additional file 1: Table S1) revealed no
complex-specific co-expression patterns, in agreement
with the trends observed in the clustering approach above:
complex I co-expression distributions are similar for indi-
vidual OXPHOS complexes (Fig. 3b, P = 0.33, Kruskal-
Wallis test). In fact, expression profiles of complexes III, IV
and V tend to be more similar to the average profile of
complex I (i.e. have higher median complex I co-expression
scores) than those of complex I genes themselves, support-
ing the notion that mRNA expression of OXPHOS genes is
jointly regulated. The possible exception is complex II, sub-
units of which tend to show less co-expression with com-
plex I genes (though not statistically significantly different)
than do subunits of complexes III, IV and V.
Interestingly, assembly factors (including those involved
in assembly of complex I itself ) have a significantly lowerco-expression with complex I than structural subunits
(P = 1.8 × 10−8, Kruskal-Wallis test, Fig. 3b) and are
more similar to other mitochondrial genes, confirming
that their expression profiles are significantly different
from OXPHOS subunits (Fig. 2b). Thus, the complex
I-like expression profile seems specific for OXPHOS
subunits compared to assembly factors or other genes
encoding mitochondrial proteins, but does not distin-
guish individual complexes.
Genes that consistently co-express with complex I
under different conditions in different cells are likely to be
functionally related, for example by being involved in
OXPHOS biogenesis or its regulation. To identify such
potential genes we considered the top 5 % of complex I
co-expression values, corresponding to a co-expression
score cutoff of 0.54 (close to a local peak in the frequency
distribution of co-expression scores, Figs. 3 and Additional
file 2: Figure S5, Additional file 4: Table S3). This cutoff
captures a total of 684 nuclear genes, including 43 %
(16/37) of the complex I subunits, 42 % (15/38) of
the other OXPHOS subunits, three assembly factors
(NDUFAF3, ACAD9, C19orf79) and 96 other known
mitochondrial genes. Functional classification of these
top-ranking genes using DAVID [11] reveals a program
that fits the biogenesis and breakdown of OXPHOS pro-
teins (Additional file 5: Table S4). Gene groups with the
highest enrichment scores (ES) other than OXPHOS (37
genes, ES 12, mostly complex I/III/IV/V genes) are
translation (51 genes, ES 23, mostly (mito)ribosomal
genes), ribonuclear processing (12 genes, ES 8) and quality
control (14/15 genes, ES 8/6, mostly ubiquitin and
proteasome-related genes). That plasticity in transcription
of metabolic/mitochondrial genes is tightly coupled to pro-
teolytic breakdown of the involved activators was recently
highlighted by Catic et al. [12] and could explain the en-
richment of the latter group. Two additional enriched gene
groups are of potential interest. The first group (ES 21)
contains PRELID1 (mitochondrial morphology and
function) [13], CHCHD2 (regulator of cytochrome oxi-
dase) [14], ISOC2 (tumor development) [15], and MRPL53
(a mitochondrial ribosomal protein also found in [16] in a
putative ribonucleotide complex with LRPPRC and SLIRP).
The second (ES 7) contains 7 genes including the complex
I assembly factor ACAD9, ETFA and ETFB (involved in
Fig. 3 All OXPHOS complexes co-express with complex I, but assembly factors follow divergent transcriptional programs. Histograms (a) and boxplots
(b) of co-expression scores with known complex I genes. Genes are grouped as OXPHOS, mitochondrial (nuclear genes encoding proteins with a function
in the mitochondria), or other genes in the genome (a). OXPHOS genes are further sub-classified into individual complexes and assembly factors (b). The
shaded grey area represents the top 5 % of nuclear genes co-expressing with complex I, which are included in the TF binding site enrichment analysis.
The dashed line marks the cutoff score (0.54). Groups are mutually exclusive, i.e. genes occur only in one group; complex I-V genes together
with assembly factors make up the OXPHOS group. Histogram counts (a) were normalized to a maximum of 1 for each gene set. Colored
boxes in boxplots (b) represent the 50 % of data points above (×0.75) and below (×0.25) the median (×0.50; the black line within the box). Vertical lines
(whiskers) connected to the boxes by the horizontal dashed lines represent the largest and the smallest non-outlier data points (which are plotted as
individual dots). P values comparing two groups are from Mann–Whitney U tests and those comparing multiple groups are from Kruskal-Wallis tests
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protein synthesis) [17].
Nuclear OXPHOS genes as a group are regulated by a
common set of known and novel candidate OXPHOS
transcription factors
Next, we analyzed potential transcriptional regulators of
the 684 (top 5 %) nuclear genes having the highest co-
expression with complex I. We obtained conserved tran-
scription factor binding sites (TFBS) for 218 unique TFs
in the promoter regions of 16,298 human genes from a
comparative evolutionary analysis of the genomes of 29
placental mammals [18]. This information is independ-
ent of experimental conditions and cell type and is
therefore typically well suited for exploratory analysis
aimed at prioritizing which TFs may regulate a biological
system (see Discussion). The data include at least one
conserved TFBS in 606 of the 684 genes (89 %) with the
highest complex I co-expression values (Fig. 1).
Genes that co-express with complex I are significantly
enriched for 12 TFs compared to the background of allhuman genes after correction for testing multiple TF
(Benjamini-Hochberg-corrected Fisher’s exact P < 0.05,
Table 1 and Additional file 6: Table S5): GABP, Elk1,
Nrf-1, Sp1, Klf7, Sp4, Ehf, znf143, Myc, YY1, Ebox, and
Tel2. Ten additional TFs are significantly enriched when
they are evaluated individually (i.e. without correcting
for multiple testing; Fisher’s exact P < 0.05, Table 1 and
Additional file 6: Table S5).
Virtually all known OXPHOS transcription regulators
are present among these 22 enriched factors, including
GABP, NRF1/2, SP1, YY1, E-box. For example, the nuclear
respiratory factors 1 and 2 (NRF1 and NRF2) have ranks 3
and 20 (out of 218 TFs tested, P = 1.0 × 10−15 and 0.033,
respectively). Furthermore, NRF1 ranks first in the analysis
of known complex I genes, and is also strongly over-
represented in complex II-V genes and OXPHOS assembly
factors (Table 2). The most significantly enriched TF for
complex I co-expressing genes is GABP/NRF2 (35 % of co-
expressing genes, 2.1-fold enrichment compared to all
genes, P = 1.8 × 10−28). NRF2 belongs to the ETS family of
transcription factors, which also contains ETS1 (rank 17,
Table 1 Transcription factor binding site enrichment in promoter regions of the top 5 % complex I co-expressing nuclear genes
Background: all human genes. Listed are all individually significantly enriched TFs (i.e. without correcting for multiple testing; Fisher’s exact P < 0.05). TFs with
Benjamini-Hochberg-corrected Fisher’s exact P < 0.05 are shaded in grey. TFs with a known role in OXPHOS biogenesis are in bold See Additional file 6: Table S5 for
detailed results
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of complex I co-expressing genes are SP1 (rank 4, P = 1.2 ×
10−12), YY1 (rank 10, P = 6.3 × 10−4), CREB (rank 21, P =
0.041), the E-box regulatory motif (rank 11, P = 1.3 × 10−3)
and E-box factor c-Myc (rank 9, P = 2.7 × 10−5). PGC-1-related coactivators (PRC), such as PGC-1(α) and PGC-1β,
are known to act through PPAR(α) (rank 14, P = 8.6 × 10−3)
and PPARγ (rank 16, P = 0.012). Aside from known regula-
tors, our analysis also identified six TFs not previously
linked to OXPHOS gene expression (see Discussion): ELK1
Table 2 Transcription factor binding site enrichment in promoter regions of OXPHOS subunits and assembly factors
Background: all human genes. Listed are all individually significantly enriched TFs (i.e. without correcting for multiple testing; Fisher’s exact P < 0.05). TFs with
Benjamini-Hochberg-corrected Fisher’s exact P < 0.05 are shaded in grey. Numbers in parentheses indicate the number of genes for which there is conserved
TFBS data. Nrf-1 is marked in bold
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SP4 (rank 6, P = 1.9 × 10−8), EHF (rank 7, P = 2.2 × 10−8),
ZNF143 (rank 8, P = 3.6 × 10−7), and TEL2 (rank 12,
P = 2.6 × 10−3).
As we have shown above, expression clustering and co-
expression analysis indicate joint regulation of OXPHOS
genes as a group, rather than specific regulation of
individual complexes. We next asked whether there is
also no evidence for complex-specific regulation in
the conserved TF binding sites. Promoter regions of com-
plex I subunits are significantly enriched only for Nrf-1
binding motifs (40.6 % of complex I genes, 3.2-fold enrich-
ment, Fisher’s exact P = 8.3 × 10−5, Table 2A). However,
Nrf-1 is not specific for complex I genes as it is also over-
represented in subunits of complexes II, III, IV and V
(32.4 % of complex II-V genes, 2.5-fold enrichment,
Fisher’s exact P = 2.6 × 10−3, Table 2B) and in OXPHOS
assembly factors (25.7 % of assembly factors, 2.0-fold
enrichment, Fisher’s exact P = 0.030, Table 2C). Thus, it
appears that there are no significantly over-representedtranscription factors among the 218 tested that regulate
specific OXPHOS complexes, confirming the patterns of
general OXPHOS subunit regulation observed in the
(co-)expression data.
Discussion
Disorders of the oxidative phosphorylation (OXPHOS)
system are rare but devastating energy deficiencies. To date,
the genetic basis of a large fraction (estimates range from
40–70 %) of these disorders remains enigmatic [4, 5]. When
no mutations are found in any of the known OXPHOS
subunits and assembly factors, a possible explanation may
be found in the genes that control their expression, such
as transcriptional (co-)activators. A specification of which
of these factors control OXPHOS gene expression, and
how, would be helpful.
Large-scale gene expression analyses have previously re-
vealed co-expression of genes involved in the OXPHOS
system [19–25]. The associated transcription program is
moderated by a set of (co-)activators, including PGC-1α,
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focused on the possibility of individual expression programs
for individual OXPHOS complexes [23]. In this study, only
genes within OXPHOS complexes I and IV showed moder-
ately higher degrees of co-expression with each other than
with OXPHOS genes as a whole. However, no specific
TFs (among 150 families tested), conserved across
three organisms (human, mouse, rat), could be identi-
fied to explain this result.
We aimed to further investigate the existence of separ-
ate expression programs for individual OXPHOS com-
plexes. To this end we investigated the transcription
program for OXPHOS genes in complex I-deficient cells
and assessed the regulatory elements involved. We used
complex I deficient cell lines and controls in order to
discriminate complex I-related expression responses
upon drug treatment. To elicit a metabolic transcrip-
tional response we incubated the cells with and without
chloramphenicol, AICAR, and resveratrol. The effects of
these incubations were generally similar between con-
trols and patients. Chloramphenicol resulted in an accu-
mulation of mitochondrial mRNA, likely due to the
block in translation. Furthermore, after chloramphenicol
and AICAR treatment, we observed contrasting changes
in the expression of subsets of mitochondrial OXPHOS
genes (COX1/ND4/ND4L/ND5/ND6 vs ATP8/ND2/
ND3) (Fig. 2a).
Chloramphenicol inhibits mitochondrial translation,
hence the observed changes in transcript levels are likely
the consequence of disrupted mitochondrial translation.
Recent studies have highlighted feedback mechanisms
between mitochondrial translation and transcription. For
example, ribosome subunit MRPL12 interacts with
mitochondrial polymerase POLRMT to enhance mito-
chondrial transcription [26, 27]. In addition, POLRMT
interacts with 12S rRNA methyltransferase h-mtTFB1 as a
possible checkpoint for 28S and 55S ribosome assembly
[28]. The changes in transcript levels that we observe
upon inhibition of translation are not correlated with
respiratory chain complex, position on the mitochondrial
genome or mitochondrial strand of origin. How the
abovementioned interactions could affect the levels of
individual mitochondrial transcripts is unclear and likely
partly controlled by regulatory proteins. A recent example
of such a protein is FASTKD5, required for the matur-
ation of a subset of mitochondrial OXPHOS mRNA’s,
primarily COX1 [29].
Although our analysis of mitochondrial and nuclear
OXPHOS gene transcription did not reveal complex-
specific expression patterns, we did observe a significantly
different expression profile for nuclear OXPHOS subunit
genes versus other genes encoding proteins localized to
the mitochondria, supporting differential nuclear gene
regulation of a sub-mitochondrial process. Interestingly,OXPHOS assembly factors showed expression profiles
that are significantly different from OXPHOS subunits:
assembly factor expression tends to be more similar to
non-OXPHOS mitochondrial genes. For example, the
iron-sulfur cluster protein NUBPL (IND1) [30] is a
complex I assembly factor with an expression profile very
different from OXPHOS subunits (Fig. 2b) and low co-
expression with complex I subunits (at ~0.3 is has the
third lowest co-expression score of all 39 analyzed
OXPHOS assembly factors). These findings suggest that
expression of at least some assembly factors is controlled
by other factors than that of subunits. This is perhaps not
surprising considering that assembly factors can play mul-
tiple roles not exclusive to the biogenesis of OXPHOS
complexes, for example in translation, membrane inser-
tion, or the incorporation of prosthetic groups.
In our expression data of complex I-deficient cells,
684 genes represent the top 5 % of nuclear genes that
co-express with known complex I genes. Among these
genes are many subunits of other OXPHOS complexes,
confirming that different OXPHOS complexes have
highly similar expression profiles. Other highly enriched
gene groups in the top complex I co-expressing genes
are those for translation and for quality control. Of par-
ticular interest are a number of genes implicated in RNA
processing and a subset of fatty acid oxidation genes.
For example, ACAD9 is essential for complex I assembly
and plays no obvious role in fatty acid oxidation, despite a
highly conserved fatty acid oxidation active site [31, 32].
ACAD9 (Fig. 2b) and two genes actually involved in
fatty acid metabolism, ETFA and ETFB, have high co-
expression with complex I subunit genes (scores ~0.6),
while ACADVL, ACADM, and ACADS, which are evolu-
tionarily related to ACAD9, all have lower scores of ~0.4.
Co-expression of ACAD9 and a number of key fatty acid
oxidation genes with complex I hints towards a possible
functional link between these two metabolic pathways.
To explore which TFs may be important for regulating
genes that co-express with complex I, we made use of a
previously published data set of TF binding sites that are
conserved across 29 mammals [18]. The conserved
TFBS are detected solely on the basis of genome se-
quence and are therefore independent of experimental
conditions and cell type [33]. In contrast, binding sites
identified in for example ChIP-sequencing experiments,
such as generated by the ENCODE consortium [34], are
specific to cell type and experimental conditions. Al-
though the conserved TFBS data has been shown to
agree well with experimentally measured ChIP-seq bind-
ing sites [18], only a subset of TFs have been measured
across many different cell types and conditions. There-
fore, sequence-conserved TFBS data such as used in this
study is typically well suited for prioritizing which TFs
may regulate a biological system. Indeed, we also
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from ENCODE ChIP-seq peaks, either by creating vari-
ous composite data sets that union all tissues and condi-
tions measured, or by analysis of specific cell types
relevant to mitochondrial functioning such as skeletal
muscle and heart cells. The union data sets produced very
large enrichments for almost all TFs tested, while the
tissue-specific data lacked power and produced not a sin-
gle over-represented TF. Thus, neither of these ap-
proaches, in our hands, were insightful for prioritizing TFs
involved in complex I co-expression, or in fact for various
other biological systems generally unrelated to mitochon-
drial function.
Analysis of conserved TF binding sites in promoter re-
gions revealed 22 over-represented TFs compared with
their genomic abundance. The enriched TFs (Table 1)
correspond well with known OXPHOS regulators [35,
36]. However, several over-represented TFs have not
been previously implicated in the regulation of complex
I or OXPHOS in general. For example, ELK1 is the sec-
ond strongest enriched TF in genes that co-express with
complex I (P = 8.6 × 10−27) and belongs to the ETS fam-
ily of transcription factors, which also includes known
OXPHOS regulators NRF2, GABP, and ETS1. Interest-
ingly, ELK1 has been linked to primary respiratory
chain disease: its target genes show large differential
expression between muscle cells and fibroblasts of
patients [37]. EHF (ESE3, rank 7, P = 2.2 × 10−8) and
TEL2 (ETV7, rank 12, P = 2.6 × 10−3) are two other
ETS family members.
SP4 (rank 6, P = 1.9 × 10−8), together with SP1 and
KLF7 (rank 5, P = 1.5 × 10−11) part of the Krüppel-like
family of TFs, was recently implicated in the regulation
of cytochrome c oxidase (OXPHOS complex IV) gene
expression in primary neurons [38]. In addition, SP4
regulates the three mitochondrial transcription factors
TFAM, TFB1M, and TFB2M, and the complex IV
assembly protein SURF1. Thus, the high rank of this TF
fits with its proposed role in OXPHOS gene regulation.
Zinc finger protein 143 (ZNF143; complex I co-
expression rank 8, P = 3.6 × 10−7; known complex I genes
rank 2, P = 7.2 × 10−3) is a transcriptional activator for
selenocysteine tRNA (tRNAsec). During mitochondrial
respiratory chain dysfunction, ZNF143 upregulates tRNA-
sec, which results in increased expression of glutathione
peroxidase 1 (GPX1) [39]. This mechanism has been
proposed to protect cells from oxidative stress damage
in conditions of respiratory chain dysfunction. In
addition, ZNF143 binds to HCFC1, which is a common
component of active CpG island promoters and coin-
cides with YY1 and GABP, both relevant to OXPHOS
biogenesis [40]. Taken together, ZNF143 is a strongly
enriched regulator of genes that co-express with com-
plex I across expression data of complex I-deficientpatients. Further investigation of the transcription fac-
tors newly identified by our analyses may provide new
clues towards gene regulation in deficiencies of the
oxidative phosphorylation system.
Conclusions
To find new leads for explaining the many genetically unex-
plained cases of OXPHOS deficiency we have explored
mitochondrial and nuclear gene expression and transcrip-
tional elements of OXPHOS subunits and assembly factors
in human complex I-deficient cells. We found that genes of
the OXPHOS system co-express distinctly from other
genes encoding mitochondrial proteins but found no sup-
port for distinct expression profiles for individual com-
plexes. Genes encoding OXPHOS assembly factors follow
an expression program different from that of OXPHOS
subunits, suggesting that regulation of biogenesis occurs via
different transcriptional activators. Many regulators of
genes that co-express with complex I are well-established
factors for OXPHOS biogenesis. However, for six factors,
we suggest for the first time a link with transcriptional
regulation of OXPHOS genes. The physiological relevance
of these factors will need to be tested.
Methods
Cell culture and RNA isolation
Control (internal culture no #4996 and #MW35) and pa-
tient (internal culture no #5170 and #9170) fibroblasts
were cultured in M199 medium (Life Technologies) sup-
plemented with 10 % fetal calf serum (v/v) and penicillin/
streptomycin. These cultures were exposed for 72 h in the
same medium with the addition of 125 uM chlorampheni-
col, 75 uM resveratrol, 500 uM AICAR, or 0.01 % DMSO
(vehicle). Duplicate treatments were harvested as two
confluent T175 flasks (~20 million cells) for two control
and two complex I-deficient patient cell lines, resulting in
a total of 32 samples for RNA isolation.
RNA sequencing
RNA was isolated using the Purelink RNA Mini Kit (Life
Technologies). RNA was treated with DNAse and quality
control was performed (OD260/280 = 1.8 ~ 2.2; OD260/
230 ≥ 2.0; RIN ≥ 7.0; 28S: 18S > 1.0). Two 2 μg of RNA was
analyzed using Illumina HiSeq2000 at least 10M clean
reads per sample (BGI Genomics, Hong Kong).
RNA-seq data analysis
Raw sequence data was filtered for reads that contain adap-
tors in their sequence (0.5 %) and with more than 50 % of
low quality base calls (quality value < = 5, 1.1 % of total
reads). 98.4 % or 10,270,698 of short reads passed these cri-
teria. After filtering the reads were mapped to the reference
using SOAP2 pipeline [41] allowing for 1 or 2 mismatched
bases. Between 80 and 89 % of reads, depending on the
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mRNAs, with 44 %–52 % uniquely to a single gene pos-
ition. 18–24 % gene transcripts were covered across their
full length (90–100 % of the transcript length) and 17–18 %
of genes were covered for less than 10 % of their transcript
length. Reads were subsequently mapped onto reference
gene sequences to calculate RPKM (Reads Per Kb per
Million mapped reads) [42]. This procedure resulted in ex-
pression values in at least one of the 32 samples for 19,426
genes. Of these, 13,700 genes were present in multiple ex-
periments that allowed further analyses. The raw RPKM
values were log-transformed and median-centered
(median = 1.0). For analysis of the transcript levels of
mtDNA-encoded genes we did not take into account
non-protein coding genes, e.g., mitochondrially
encoded 12S and 16S RNA (MT-RNR1, MT-RNR2)
and tRNA leucine 1 (MT-TL1). Reproducibility of total
mRNA measurements of the mtDNA encoded genes for
the biological replicates was very high (R2 = 0.88, average
difference between measurements 1.9 %; 0.1 %–12 %). The
transcript levels of mitochondrial genes were normalized in
the same way as nuclear genes.
Co-expression calculations
For the complex I co-expression analysis we take into
account all nuclear encoded subunits of the complex
and its assembly factors NDUFAF1-4, TMEM126B [43],
and ACAD9 [31]. Pearson correlations of expression
were calculated for each of the 13,684 genes with every
gene that encodes a complex I subunit or assembly
factor. The correlation values are based on the expression
measurements of the 32 samples. We then calculated for
each gene the average co-expression with the extended
complex I gene set (i.e., the genes mention above).
c g; S ¼ NDUFA1;NDUFA2;…½ ð Þ
¼ avg
g 0∈S
ρ e g½ ; e g 0½ ð Þ≥0
ρ e g½ ; e g 0½ ð Þ
where c(g,S) is the co-expression of gene g with gene set
S, where S is the extended set of complex I genes and
assembly factors, ρ denotes the Pearson correlation, and
e[g] is the expression vector in 32 conditions and cell
types for gene g.
Similarly to expression patterns observed for all
OXPHOS genes, complex I subunits and their assembly
factors exhibit slightly divergent transcriptional pro-
grams. Additional file 2: Figure S6 reveals that complex I
core subunits cluster together separately from assembly
factors. The first (and largest) group is composed mostly
of core subunits (from NDUFA11, top, to NDUFA6).
Two smaller categories, with respectively seven and sixsubunits, additionally contain complex I assembly factors
(NDUFAF1, NDUFAF5 in the second subclass; TMEM126B,
NDUFAF2, NDUFAF4 in the third). Resveratrol and
AICAR experiments appear to be most discriminative
for the subgroup classification as the first subclass
(subunits) shows low expression in resveratrol and
AICAR in patients, and higher expression in AICAR-
treated controls (Additional file 2: Figure S6). The smaller
two subclasses of complex I genes do not exhibit such
clear expression patterns. To account for the fact that sub-
classes fall under different transcriptional programs, we
only considered Pearson correlations greater than 0.
This increases the sensitivity of finding genes that fall
under the transcriptional program of one of the sub-
classes (positive correlation), but not the other (negative
correlation, which is not taken into account).
We selected a subset of 684 genes (representing the
top 5 % of complex I co-expression scores) for down-
stream analyses. We determined this cutoff by three cri-
teria: (i) it captures almost half (42 %) of the known
OXPHOS subunits, (ii) it is close to a local peak in the
frequency distribution of co-expression scores (Figs. 3
and Additional file 2: Figure S5), and (iii) the size of the
resulting set of genes (684) is well suited for enrichment
analysis, both on the level of functional classification
and gene ontology as well as in terms of conserved tran-
scription factor binding sites (see below).
Conserved transcription factor binding site data
Data on conserved transcription factor binding sites (TFBS)
in human were obtained from a comparative analysis of 29
genomes of placental mammals, such as primates, rodents
and many farm animals [18]. In this study, transcription
factor (TF) regulatory motifs were collected from the
TRANSFAC [44] and Jaspar [45] databases, and several
protein binding microarrays [46–48]. The presence of indi-
vidual motif instances (putative TFBS) was predicted across
the human genome based on conservation across the 29
mammals: for each motif match in human, the smallest
phylogenetic subtree was calculated that contains the hu-
man motif and aligned motifs in other species [33]. TFBS
were identified at a false discovery rate of 60 % and show
reasonable agreement with experimentally measured ChIP-
seq binding sites [18].
To identify putative regulators of a gene, we used
conserved TFBS in promoter regions of genes, which
were defined as 4 kilobase (kb) windows centered at all
annotated transcription start sites of the gene (i.e. 2 kb
upstream and 2 kb downstream of each transcription
start site). This approach identifies instances for 361
regulatory motifs corresponding to 218 unique TFs
(most TFs have multiple similar binding motifs) in the
promoters of 16,298 genes, with a median of 7 (average 9.19)
unique TFs per target gene.
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We used the Fisher’s exact test to calculate statistical
over-representation of TFs regulating a gene set of
interest compared to a background (e.g. all genes in
the human genome, or all OXPHOS genes). Enrich-
ment P values were corrected for testing multiple TFs
(218 in total) using the Bonferroni or Benjamini-
Hochberg false discovery procedures. TFs were judged to
be significantly enriched at a significance level of 5 %.
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